You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-PD1 Therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

Not yet recruiting
  • Muscle-Invasive Bladder Carcinoma
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center, Sun Yat-sen University
Aug 3, 2023

NSCLC, Immunotherapy Trial in Ann Arbor (Dexamthasone)

Terminated
  • Non-Small Cell Lung Cancer
  • Immunotherapy
  • Ann Arbor, Michigan
    VA Ann Arbor Healthcare System, Ann Arbor, MI
Jan 6, 2023

Lung Cancer Trial in Madrid (Microbiota Transplant plus anti PD1 therapy, anti PD1 therapy)

Recruiting
  • Lung Cancer
  • Microbiota Transplant plus anti PD1 therapy
  • anti PD1 therapy
  • Madrid, Spain
    Hospital Universitario Ramón y Cajal
Oct 3, 2022

Thyroid Dysfunction Induced by Anti-PD-1 Therapy in Advanced

Completed
  • Carcinoma
  • no intervention
  • Jinan, Shandong, China
    Qilu Hospital, Shandong University
Oct 23, 2022

Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Camrelizumab (anti-PD-1 inhibitor), Apatinib

Recruiting
  • Oral Squamous Cell Carcinoma
  • +3 more
  • Camrelizumab (anti-PD-1 inhibitor)
  • Apatinib (anti-VEGFR inhibitor)
  • Shanghai, Shanghai, China
    Ninth People's Hospital, Shanghai Jiao Tong University School of
Oct 8, 2022

Recurrent Human Papillomavirus Type 16 Associated Cancer Trial in Birmingham, Baltimore (HPV 16 TA-CIN)

Withdrawn
  • Recurrent Human Papillomavirus Type 16 Associated Cancer
  • HPV 16 TA-CIN
  • Birmingham, Alabama
  • +1 more
Nov 29, 2022

Advanced Stage NSCLC Trial in Amsterdam ([18F]F-AraG PET scan)

Recruiting
  • Advanced Stage Non-small Cell Lung Cancer
  • [18F]F-AraG PET scan
  • Amsterdam, Netherlands
    Amsterdam UMC, location VU University Medical Center
Jan 17, 2023

Squamous Cell Carcinoma of the Head and Neck Trial in Stanford ([18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.)

Completed
  • Squamous Cell Carcinoma of the Head and Neck
  • [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
  • Stanford, California
    Stanford Hospital and Clinics
Dec 1, 2022

Ovarian Cancer Stage IV, Ovarian Cancer Stage III, Ovarian Cancer Stage 3 Trial in Washington, Hackensack (NY-ESO-1 Peptide

Not yet recruiting
  • Ovarian Cancer Stage IV
  • +2 more
  • Washington, District of Columbia
  • +2 more
Jul 28, 2022

Monitoring T Cell Responses in Melanoma, Lung and Other Cancer

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +9 more
  • Biospecimen Collection
  • Electronic Health Record Review
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Oct 4, 2023

Solid Tumor, Peritoneal Metastases, Peritoneal Cancer Trial in Haifa, Jerusalem, Ramat Gan (Allocetra-OTS, nivolumab)

Recruiting
  • Solid Tumor
  • +2 more
  • Haifa, Israel
  • +2 more
Oct 12, 2022

Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 Trial in

Recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +6 more
  • Biopsy
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 20, 2023

Head and Neck Squamous Cell Carcinoma Trial (TTI-101, Pembrolizumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Dec 20, 2022

Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous

Active, not recruiting
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • +3 more
  • 200 mg Pembrolizumab
  • +2 more
  • Miami, Florida
  • +6 more
Jan 9, 2023

Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer Trial in Shanghai (SHR-1210, Famitinib)

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • Shanghai, Shanghai, China
    Huadong Hospital Affiliated to Fudan University
Jun 30, 2022

Head Neck Cancer Trial in Madison (NKTR-214, anti-PD-1 therapy, Palliative Radiation)

Active, not recruiting
  • Head and Neck Cancer
  • Madison, Wisconsin
    University of Wisconsin
May 9, 2022

Immunotherapy, Analgesia, NSCLC Trial in Tianjin (neoadjuvant immunotherapy, Neoadjuvant chemo)

Recruiting
  • Immunotherapy
  • +3 more
  • neoadjuvant immunotherapy
  • Neoadjuvant chemotherapy
  • Tianjin, Tianjin, China
  • +2 more
Aug 23, 2022

Unresectable Melanoma, Metastatic Melanoma, Stage III Melanoma Trial in Boston (Sargramostim (GM-CSF), Pembrolizumab

Recruiting
  • Unresectable Melanoma
  • +3 more
  • Sargramostim (GM-CSF)
  • Pembrolizumab (anti-PD-1)
  • Boston, Massachusetts
  • +1 more
Jul 6, 2022

Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anti-EGFR and PD-1 inhibitor arm
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 26, 2023

Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Guangzhou (PD-1 combined with SBRT)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Oligometastatic Disease
  • PD-1 combined with SBRT
  • Guangzhou, Guangdong, China
    Mian Xi
Dec 18, 2022

Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Metastatic Esophageal Squamous Cell Carcinoma Trial in Shanghai

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • +2 more
  • LDRT+CFRT
  • +2 more
  • Shanghai, China
  • +1 more
Aug 3, 2023

Metastatic Melanoma Trial in Irvine, Newport Beach (AV-MEL-1)

Recruiting
  • Metastatic Melanoma
  • Irvine, California
  • +1 more
Dec 14, 2021

Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)

Not yet recruiting
  • Colorectal Cancer
  • Serplulimab + FOLFOXIRI
  • Radiation therapy
  • (no location specified)
Oct 24, 2023

Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Durvalumab
  • Rintatolimod
  • Rotterdam, Zuid-Holland, Netherlands
    Erasmus MC
Jun 23, 2023

Malignant Melanoma Trial in Germany, Italy (4SC-202 in combination with Pembrolizumab)

Completed
  • Malignant Melanoma
  • 4SC-202 in combination with Pembrolizumab
  • Essen, Germany
  • +6 more
Feb 3, 2022